Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | RARB | P10826 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | RXRA | P19793 | 3/20 | 0.50 |
| ▸ | RXRB | P28702 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1244791 | 0.98 | SRD5A2 (0.59) | SRD5A2MEN1CYP1A2KMT2ARARB | |
| SCHEMBL29098742 | 0.86 | SRD5A2 (0.61) | SRD5A2MEN1CYP1A2KMT2ARARB | |
| Terephthalic Acid SCHEMBL31728631 | 0.85 | TSHR (0.67) | SRD5A2MEN1CYP1A2KMT2ARARB | |
| SCHEMBL16840188 | 0.84 | SRD5A2 (0.59) | SRD5A2MEN1CYP1A2KMT2ARARB | |
| SCHEMBL29410187 | 0.83 | CYP1A2 (0.59) | SRD5A2MEN1CYP1A2KMT2ARARB | |
| SCHEMBL12648649 | 0.83 | CYP1A2 (0.59) | SRD5A2MEN1CYP1A2KMT2ARARB | |
| SCHEMBL715285 | 0.83 | CYP1A2 (0.59) | SRD5A2MEN1CYP1A2KMT2ARARB | |
| Terephthalic Acid SCHEMBL1243625 | 0.83 | TSHR (0.80) | SRD5A2TSHRTP53ALOX15ALDH1A1 | |
| SCHEMBL8349213 | 0.82 | EPHX2 (0.47) | MEN1KMT2ANR1H4EPHX2ALDH1A1 | |
| SCHEMBL11772204 | 0.81 | SRD5A2 (0.65) | SRD5A2MEN1CYP1A2KMT2ARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4234552-A2 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3426244-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3303415-B1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC (CH) | 2022-12-28 | — | — | EP | disclosed |
| US-11535593-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220017464-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11014882-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | NOVARTIS AG (CH) | 2019-06-18 | — | — | US | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20190071400-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1472230-A2 | ANSAMYCINS HAVING IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES | Conforma Therapeutic Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066005-A2 | ANSAMYCINS HAVING IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES | CONFORMA THERAPEUTICS CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0950057-B1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LAB (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6403575-B1 | ANTI-INFLAMMATORIES | ABBOTT LABORATORIES | 2002-06-11 | — | — | US | disclosed |
| EP-1047690-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6133253-A | NEURONAL CELL DEATH PREVENTORS AND ANTI-INFLAMMATORIES | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0950057-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | Abbott Laboratories (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999032480-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998025920-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LABORATORIES (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | SRD5A2 359/4885MEN1 3285/4885CYP1A2 2136/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | SRD5A2 43/4885MEN1 13/4885CYP1A2 95/4885 |
| US-10324311-B2 | Visible-light photoinitiators and uses thereof | SIRT5, IK, IGLV6-57 | SRD5A2 3532/4885MEN1 1837/4885CYP1A2 1874/4885 |
| US-11535593-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | SRD5A2 359/4885MEN1 3285/4885CYP1A2 2136/4885 |
| US-11014882-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | SRD5A2 359/4885MEN1 3285/4885CYP1A2 2136/4885 |
| US-20190071400-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | SRD5A2 359/4885MEN1 3285/4885CYP1A2 2136/4885 |
| US-20220017464-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | SRD5A2 359/4885MEN1 3285/4885CYP1A2 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.